Associate Director, In-Vivo Pharmacology

RayzeBio is seeking an Associate Director, In-Vivo Pharmacology to provide scientific and operational leadership across oncology programs with a focus on radiopharmaceutical therapeutics (RPTs). This role provides functional leadership to senior scientists to design and execute high-quality in-vivo studies that inform program strategy from discovery through IND-enabling development. The Associate Director will set direction, ensure alignment, and drive high-quality decision-making, while maintaining accountability for vivarium operations, animal welfare, and regulatory compliance (IACUC/AALAC). This is a highly cross-functional role that operates close to the science without serving as the primary experimentalist. The ideal candidate combines deep expertise in oncology in-vivo pharmacology with a strong sense of ownership, practical decision-making, and comfort operating at the intersection of science, operations, and compliance in a fast-moving biotech environment. Key Responsibilities • Lead the in-vivo pharmacology strategy for oncology RPT programs by supporting scientists in study design, execution, data interpretation, and translational relevance. • Serve as a scientific thought partner, providing feedback and direction on: model selection (CDX/PDX), dose and schedule rationale and endpoint definition and evaluability. Support selection of mouse strains, tumor models, activity levels, and fractionation schemes appropriate for Lu-177, Ac-225, and future RPT isotopes and modalities. • Ensure consistency, rigor, and strategic alignment across in-vivo studies supporting multiple programs from early discovery through IND-enabling development. • Own efficacy and biodistribution strategy for radiopharmaceutical programs, incorporating tumor growth kinetics, delayed response patterns, and modality-specific considerations. Ensure study designs reflect radiobiological realities. • Partner closely with dosimetry/physics, imaging, radiochemistry, biology and DMPK teams to align in-vivo studies with absorbed dose and exposure-response understanding. • Review and contribute to in-vivo pharmacology sections of study reports and IND-enabling regulatory submissions. • Serve as a point of escalation for animal care, biosecurity, or facility-related issues impacting studies and operations. Education and Experience • Ph.D. in Pharmacology, Cancer Biology, Toxicology, or related field, with 8+ years of relevant industry experience • Strong track record in in-vivo oncology pharmacology, including xenograft efficacy studies and supporting preclinical programs advancing toward IND • Demonstrated ability to lead complex, cross-functional teams/efforts and make pragmatic decisions in a fast-paced R&D environment • Working knowledge of IACUC processes, animal welfare regulations and experience supporting AALAC accreditation activities • Experience applying AI and computational tools to enhance data analysis, automate routine workflows, and support data-driven decision-making is desirable • Experience with radiopharmaceuticals, radioligand therapies, or radiation-based modalities including familiarity with biodistribution, dosimetry, and radiation biology concepts preferred We hire for skills and capabilities, not just credentials - if this role excites you, but doesn't perfectly match your resume, we encourage you to apply anyway. Compensation Overview: San Diego - CA - US: $190,539 - $230,888 The starting pay range(s) listed above is for full-time employees (FTE). You may also be eligible for additional discretionary incentive cash and stock opportunities. We determine starting pay thoughtfully - carefully considering the nature of the role, required skills, work location, schedule and the knowledge and experience you bring. Final compensation is guided by pay equity principles and applicable employment laws. Compensation programs are reviewed on an ongoing basis and may be adjusted over time to reflect evolving market factors, and individual, team or Company performance. Benefits: Subject to the terms and conditions of the applicable plans then in effect, you may be eligible to participate in our comprehensive benefit plans - including wellbeing support, retirement and financial protection benefits, and insurance offerings (medical, dental, vision, life and disability). U.S.-based exempt employees are eligible for Flexible Time Off (FTO), which provides paid time off without a set accrual limit, subject to manager approval, along with 11 paid company holidays each year. Non-exempt employees, RayzeBio employees, and employees located in Puerto Rico receive 160 hours of paid vacation annually for new hires (subject to manager approval), 11 paid company holidays, and 3 optional holidays. Depending on eligibility, employees may also have access to additional time-off benefits, including paid sick leave, up to two paid volunteer days per year, summer hours flexibility, and leaves of absence for medical, personal, parental, caregiver, bereavement, or military needs. Eligible employees also enjoy an annual Global Shutdown between Christmas Day and New Year's Day. U.S.-based job seekers can explore full benefit offerings at https://careers.bms.com/benefits RayzeBio was acquired by Bristol Myers Squibb (BMS) in 2024 and is a wholly-owned subsidiary of BMS; however, RayzeBio will continue to operate as a standalone organization.